Abstract: FR-PO258
Implementation of a CKD Panel Management Tool for Resident Physicians
Session Information
- CKD: Clinical, Outcomes, Trials - II
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Howard, Frederick Matthew, Yale School of Medicine, Cheshire, Connecticut, United States
- Connolly, James J., Yale School of Medicine, Cheshire, Connecticut, United States
- Ackley, William, Yale School of Medicine, Cheshire, Connecticut, United States
- Harada, Kaoru, Yale School of Medicine, Cheshire, Connecticut, United States
- Kunnirickal, Steffne J., Yale School of Medicine, Cheshire, Connecticut, United States
- Merchant, Naseema Banu, Yale School of Medicine, Cheshire, Connecticut, United States
- Perazella, Mark A., Yale School of Medicine, Cheshire, Connecticut, United States
Background
Chronic kidney disease (CKD) affects approximately 1 in 7 adults and over one million Veterans served by the Veterans Health Administration (VHA). These patients are at increased risk for numerous adverse sequelae, including anemia, metabolic acidosis (MA), proteinuria, mineral bone disease (MBD), and hypertension. Clinical practice guidelines have been published by the Kidney Disease: Improving Global Outcomes work group to assist clinicians in managing the sequelae of CKD, but guideline compliance was low in a test cohort of patients cared for by residents working at a VHA Medical Center.
Methods
We designed a panel management tool to provide an automated summary of guideline-based interventions relevant to each patient seen in clinic. Residents received up to 16 recommendations per patient – eight focusing on work-up of anemia, five on MBD, and one each on uncontrolled hypertension, evaluation for albuminuria, and correction of MA. Guideline compliance, both overall and for specific domains of care, was compared pre- and post-intervention using a two-sided t-test.
Results
We identified 365 encounters with patients with at least stage III CKD (eGFR < 60 ml/min/1.73 m2) during the six months prior to intervention, and 272 encounters in the first four months of our intervention. Guideline compliance increased from 53.5 ± 1.3% pre-intervention to 61.0 ± 2.5% post-intervention (p < 0.01). In a subgroup analysis, there were significant improvements in MBD testing (40.0 ± 2.4% vs 53.0 ± 2.9%) and albuminuria screening (25.6 ± 2.0% vs 42.1 ± 3.3%).
Conclusion
Implementation of a panel management tool achieved significant improvement in overall guideline compliance, with particular efficacy in the domains of MBD and albuminuria screening. The short time course of the intervention may have limited our ability to assess for improvement in blood pressure control and MA. This effective tool could be universally applied to improve the management of CKD by VHA providers.
Funding
- Veterans Affairs Support